Supreme Court backs generic drugmaker in 'skinny labeling' case

Supreme Court backs generic drugmaker in 'skinny labeling' case

statnews.com business

Key Points:

  • The Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe patents held by Amarin in a decision that makes generic drugmakers less vulnerable to lawsuits over so-called skinny lab

Trending Business

Trending Technology

Trending Health